alanylalanine (Ala-Ala)

RN given refers to (DL)-isomer

Also Known As:

Ala-Ala; D-Ala-D-Ala; D-alanine, D-alanyl-; D-alanine, L-alanyl-; D-alanyl-D-alanine; D-alanyl-L-alanine; D-alanylalanine; H-Ala-Ala-OH; H-D-Ala-D-Ala-OH; L-alanine, D-alanyl-; L-alanyl-D-alanine; L-alanyl-L-alanine; N-D-alanyl-L-alanine; N-L-alanyl-D-alanine; NSC-89598; alanyl-D-alanine; alanylalanine, (D)-isomer; alanylalanine, (D-Ala)-(L-Ala)-isomer; alanylalanine, (L)-isomer; alanylalanine, (L-Ala)-(D-Ala)-isomer; alanylalanine, (L-Ala)-(DL-Ala)-isomer; di-L-alanine; dialanine; dialanine, D,D-

Networked: 139 relevant articles (2 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - Dipeptides: 945
      - alanylalanine: 139

Experts

1.	Dai, Qiang-Sheng: 2 articles (01/2014 - 01/2014)
2.	Hua, Rui-Xi: 2 articles (01/2014 - 01/2014)
3.	Fukuhara, Hideo: 2 articles (11/2013 - 02/2012)
4.	Furihata, Mutsuo: 2 articles (11/2013 - 02/2012)
5.	Iiyama, Tatsuo: 2 articles (11/2013 - 02/2012)
6.	Inoue, Keiji: 2 articles (11/2013 - 02/2012)
7.	Kurabayashi, Atsushi: 2 articles (11/2013 - 02/2012)
8.	Miyamura, Mitsuhiko: 2 articles (11/2013 - 02/2012)
9.	Shuin, Taro: 2 articles (11/2013 - 02/2012)
10.	Ahn, Sang-Gun: 2 articles (01/2012 - 09/2010)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2014 - "Overall, significantly increased cancer risk was associated with the variant Ser133 when all studies were pooled (Ser vs Ala: OR=1.51, 95% CI=1.08- 2.12, Pheterogeneity≤0.001; Ser/Ser+Ala/Ser vs Ala/Ala: OR=1.55, 95% CI=1.08-2.22, Pheterogeneity ≤ 0.001). " 01/01/2022 - "According to our data, the polymorphism of RASSF1A Ala133Ser was associated with tumor risk (Ser vs. Ala: OR = 1.68,95% CI = 1.20-2.36; Ala/Ser vs. Ala/Ala:OR = 1.63,95% CI = 1.16-2.27; Ser/Ser vs. Ala/Ala:OR = 3.06,95% CI = 1.91-4.89; Recessive model:OR = 2.67, 95% CI = 1.66-4.32; Dominant model: OR =1.72, 95% CI =1.20-2.45). " 01/01/2014 - "In addition, in subgroup analyses by ethnicity, it was found that the RASSF1A Ala133Ser polymorphism was associated with overall cancer risk in Asians (Ser vs Ala: OR=1.37, 95% CI=1.06-1.77, Pheterogeneity=0.06) and Caucasians (Ser/Ser+Ala/Ser vs Ala/Ala: OR=2.21, 95% CI=1.01-4.82, Pheterogeneity≤0.001). " 01/01/2014 - "Overall, our results did not suggest significant associations between Ala variant (Ala/Ala or Ala/Val genotype) and cancer risk. " 01/01/2001 - "In the UFT(-) group, the amount of FH4 in Ala/Val-type cancer tissue was higher than that in Ala/Ala-type (1.50 +/- 1.13 versus 0.72 +/- 0.64, p < 0.05). "
2.	Insulin Resistance 11/01/2006 - "Meta-analysis of Ala/Ala homozygotes more clearly demonstrated the association with greater insulin sensitivity of carriers of the Ala allele." 09/01/2012 - "Ala/Ala genotype of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with obesity and insulin resistance in Asian Indians." 01/07/2009 - "We demonstrate, using a Pro12Ala knockin model, that on chow diet, Ala/Ala mice are leaner, have improved insulin sensitivity and plasma lipid profiles, and have longer lifespans. " 01/01/2011 - "Homeostasis insulin resistance model assessment and 2-h plasma glucose were significantly lower among Val-allele carriers compared to the Ala/Ala genotype within the NGT group. "
3.	Breast Neoplasms (Breast Cancer) 09/01/2010 - "Overall, no significant associations were found between MnSOD Val16Ala polymorphism and breast cancer risk when all studies pooled into the meta-analysis (Val/Ala vs. Val/Val: OR = 1.022, 95% CI = 0.981-1.064; Ala/Ala vs. Val/Val: OR = 1.006, 95% CI = 0.934-1.083; dominant model: OR = 1.013, 95% CI = 0.962-1.066; and recessive model: OR = 0.985, 95% CI = 0.931-1.042). " 11/01/2009 - "Compared with the MnSOD Val/Val genotype, the MnSOD Val/Ala or MnSOD Ala/Ala genotype was not significantly associated with the overall risk for breast cancer. " 12/01/2005 - "As compared with Val/Val genotype, we found no association between MnSOD Ala/Val (OR = 0.98, 95% CI: 0.79-1.21) and Ala/Ala (OR = 1.00, 95% CI: 0.79-1.28) genotypes and breast cancer. " 01/01/2004 - "Breast cancer risk was slightly elevated in women with Ala/Ala genotype (odds ratio [OR] 1.3, 95% confidence interval [CI] 0.7-2.3), particularly among premenopausal women (OR 1.8, 95% CI 0.9-3.7), as compared with those with Val/Val genotype. " 04/01/2013 - "Overall, no significant associations were found between MTHFR Glu429Ala polymorphism and breast cancer risk when all studies were pooled into the meta-analysis (Glu/Glu vs Ala/Ala: OR = 0.891, 95 % CI = 0.782-1.015; Glu/Ala vs Ala/Ala: OR = 0.874, 95 % CI = 0.760-1.006; dominant model: OR = 0.885, 95 % CI = 0.775-1.012; and recessive model: OR = 0.989, 95 % CI = 0.931-1.051). "
4.	Prostatic Neoplasms (Prostate Cancer) 03/01/2009 - "Breast and prostate cancer risk was elevated in male and female patients with the Ala/Ala genotype compared to controls (p = 0.006, odds ratio = 2.5, 95% confidence interval 1.393-4.541). " 10/01/2008 - "These data suggest that Ala/Ala MnSOD genotype in the Macedonian population could have an influence on early onset of prostate cancer, but no impact on the subsequent development of the disease." 03/01/2007 - "It was observed that carrying the Ala/Ala genotype or the Ala allele resulted in an insignificant increase in the frequency of aggressive prostate cancer compared to nonaggressive prostate cancer. " 03/01/2007 - "The Ala/Ala genotype and the Ala allele were found at statistically higher frequencies in patients with prostate cancer as compared to controls (p < 0.05). " 08/01/2003 - "These data suggest an effect of the MnSOD ala/ala genotype on the development of prostate cancer. "
5.	Urinary Bladder Neoplasms (Bladder Cancer) 10/01/2013 - "Overall, the MTHFR Ala222Val polymorphism was not associated with the development of bladder cancer in all genetic models (Ala/Ala vs. Val/Val--OR = 0.961, 95 % CI = 0.763-1.209; Ala/Ala vs. Ala/Val--OR = 0.918, 95 % CI = 0.795-1.060--Ala/Val vs. Val/Val--OR = 1.022, 95 % CI = 0.852-1.227; dominant model--OR = 0.998, 95 % CI = 0.869-1.145; recessive model--OR = 0.921, 95 % CI = 0.794-1.069; Ala allele vs. Val allele--OR = 0.957, 95 % CI = 0.857-1.067). " 09/01/2012 - "Additionally, patients carrying both Ala/Ala of MnSOD and Leu/Leu of GPX1 had the highest risk of developing bladder cancer. " 02/15/2012 - "This study was undertaken to evaluate the clinical value of photodynamic diagnosis (PDD) with intravesical and oral instillation of 5-aminolevulinic acid (ALA) (ALA-PDD), and transurethral resection of bladder tumor (TURBT) guided by ALA-PDD (PDD-TURBT) for nonmuscle invasive bladder cancer. " 10/15/2013 - "Likewise, Ala499Val was also significantly associated with an increased overall cancer risk (Val/Val vs. Ala/Ala: OR = 1.21, 95% CI = 1.07 - 1.36, p = 0.003 and recessive model: OR = 1.20, 95% CI = 1.08 - 1.34, p = 0.001) and further stratification showed an increased risk for breast and bladder cancer, particularly in Asian populations. " 06/01/2008 - "The results for Ala499Val showed a significant overall increase in cancer risk (OR 1.15; 95% CI: 1.02-1.31), and for bladder cancer in both the simple genetic model (Ala/Ala vs Val/Val) (OR 1.30; 95% CI: 1.04-1.61) and the recessive genetic model (Ala/Ala+Ala/Val vs Val/Val) (OR 1.32; 95% CI: 1.06-1.63). "

Related Drugs and Biologics

1.	Lipids
2.	Estrogen Receptors
3.	Esters
4.	valylvaline (Val-Val)
5.	1-phenyl-3,3-dimethyltriazene (PDT)
6.	Acids
7.	Antioxidants
8.	glutamyl-glutamic acid (Glu-Glu)
9.	Serine Proteases (Serine Protease)
10.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

Related Therapies and Procedures

1.	Photochemotherapy (Photodynamic Therapy)
2.	Transurethral Resection of Bladder
3.	Semiconductor Lasers
4.	Cyclotrons
5.	Therapeutics